L
Linda J. Bristow
Researcher at Merck & Co.
Publications - 53
Citations - 5277
Linda J. Bristow is an academic researcher from Merck & Co.. The author has contributed to research in topics: Agonist & Receptor antagonist. The author has an hindex of 36, co-authored 50 publications receiving 5099 citations. Previous affiliations of Linda J. Bristow include Hoffmann-La Roche & General Atomics.
Papers
More filters
Journal ArticleDOI
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.
Ruth M. McKernan,Thomas W. Rosahl,David S. Reynolds,Cyrille Sur,Keith A. Wafford,John R. Atack,Sophie J. Farrar,J Myers,G.P. Cook,Pushpinder Ferris,L Garrett,Linda J. Bristow,George R. Marshall,Alison J. Macaulay,N. Brown,Owain W. Howell,Kevin W. Moore,Robert W. Carling,Leslie J. Street,Castro Jl,C.I. Ragan,G. R. Dawson,Paul J. Whiting +22 more
TL;DR: This work created genetically modified mice with a diazepam-insensitive α1 subtype and a selective BZ site ligand to explore GABAA receptor subtypes mediating specific physiological effects and revealed that the α1Subtype mediated the sedative, but not the anxiolytic effects of benzodiazepines.
Journal ArticleDOI
Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.
TL;DR: It is indicated that systemic ketamine increases both glutamate and DA release in mPFC and that the effect on glutamate can be blocked by stimulating mP FC group II mGluR receptors.
Journal ArticleDOI
3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]- pyridine: A Potent and Highly Selective Metabotropic Glutamate Subtype 5 Receptor Antagonist with Anxiolytic Activity
Nicholas D. P. Cosford,Lida Tehrani,Jeffrey Roger Roppe,Edwin J. Schweiger,Nicholas D. Smith,Jeffrey Anderson,Linda J. Bristow,Jesse Brodkin,Xiaohui Jiang,Ian A. McDonald,Sara Rao,Mark S. Washburn,Mark A. Varney +12 more
TL;DR: Seeking to improve the properties of 2-Methyl-6-(phenylethynyl)pyridine led to the synthesis of compound 9, a highly selective mGlu5 receptor antagonist that is 5-fold more potent than 3 in the rat fear-potentiated startle model of anxiety.
Journal ArticleDOI
Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.
Martin R. Guscott,Linda J. Bristow,K. L. Hadingham,Thomas W. Rosahl,Margaret S. Beer,Josephine A. Stanton,Frances A. Bromidge,Andrew Pate Owens,Ian Thomas Huscroft,J Myers,Nadia Melanie Rupniak,Shil Patel,Paul J. Whiting,Peter H. Hutson,Kevin C. F. Fone,Stephany M. Biello,Janusz Jozef Kulagowski,George McAllister +17 more
TL;DR: These pharmacological and genetic knockout studies provide the first direct evidence that 5-HT7 receptor antagonists should be investigated for efficacy in the treatment of depression.
Journal ArticleDOI
Role of Dopamine D2-like Receptors in Cocaine Self-Administration: Studies with D2 Receptor Mutant Mice and Novel D2 Receptor Antagonists
S. Barak Caine,S. Stevens Negus,Nancy K. Mello,Smita Patel,Linda J. Bristow,Janusz Jozef Kulagowski,Daniela Vallone,Adolfo Saiardi,Emiliana Borrelli +8 more
TL;DR: It is suggested that the D2 receptor is not necessary for cocaine self-administration, but this receptor subtype is involved in mechanisms that limit rates of high-dose cocaine self–administration.